ChloroquineV1, Main, Exploration, bibRecord, 001C32

Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers

Identifieur interne : 001C32 ( Main/Exploration ); précédent : 001C31; suivant : 001C33

Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers

Auteurs : I. Fomin [Israël] ; D. Caspi [Israël] ; V. Levy [Israël] ; N. Varsano [Israël] ; Y. Shalev [Israël] ; D. Paran [Israël] ; D. Levartovsky [Israël] ; I. Litinsky [Israël] ; I. Kaufman [Israël] ; I. Wigler [Israël] ; E. Mendelson [Israël] ; O. Elkayam [Israël]

Source :

Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2006-02.

RBID : ISTEX:F1BEADA3E98709F72306672C235D47546767CB17

English descriptors

Abstract

Objective: To assess the efficacy and safety of vaccination against influenza virus in patients with rheumatoid arthritis, with special emphasis on the effect of disease modifying antirheumatic drugs (DMARDs), including tumour necrosis factor α (TNFα) blockers. Methods: 82 rheumatoid patients and 30 healthy controls were vaccinated with a split-virion inactivated vaccine containing 15 μg haemagglutinin (HA) per dose of each of B/Hong Kong/330/2001 (HK), A/Panama/2007/99 (PAN), and A/New Caledonian/20/99 (NC). Disease activity was assessed by tender and swollen joint count, morning stiffness, evaluation of pain, Health Assessment Questionnaire, ESR, and C reactive protein on the day of vaccination and six weeks later. Haemagglutination inhibiting (HI) antibodies were tested by a standard WHO procedure. Response was defined as a fourfold or more rise in HI antibodies six weeks after vaccination, or seroconversion in patients with a non-protective baseline level of antibodies (<1/40). Geometric mean titres (GMT) were calculated to assess the immunity of the whole group. Results: Six weeks after vaccination, a significant increase in GMT for each antigen was observed in both groups, this being higher in the healthy group for HK (p = 0.004). The percentage of responders was lower in rheumatoid patients than healthy controls (significant for HK). The percentage of responders was not affected by prednisone or any DMARD, including methotrexate, infliximab, and etanercept. Indices of disease activity remained unchanged. Conclusions: Influenza virus vaccine generated a good humoral response in rheumatoid patients, although lower than in healthy controls. The response was not affected by the use of prednisone or DMARDs.

Url:

https://api.istex.fr/ark:/67375/NVC-CJWVBJG1-0/fulltext.pdf

DOI: 10.1136/ard.2005.036434

Affiliations:

Israël

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 002359
to stream Istex, to step Curation: 002359
to stream Istex, to step Checkpoint: 000B00
to stream Main, to step Merge: 001C44
to stream Main, to step Curation: 001C32

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers</title>
<author><name sortKey="Fomin, I" sort="Fomin, I" uniqKey="Fomin I" first="I" last="Fomin">I. Fomin</name>
</author>
<author><name sortKey="Caspi, D" sort="Caspi, D" uniqKey="Caspi D" first="D" last="Caspi">D. Caspi</name>
</author>
<author><name sortKey="Levy, V" sort="Levy, V" uniqKey="Levy V" first="V" last="Levy">V. Levy</name>
</author>
<author><name sortKey="Varsano, N" sort="Varsano, N" uniqKey="Varsano N" first="N" last="Varsano">N. Varsano</name>
</author>
<author><name sortKey="Shalev, Y" sort="Shalev, Y" uniqKey="Shalev Y" first="Y" last="Shalev">Y. Shalev</name>
</author>
<author><name sortKey="Paran, D" sort="Paran, D" uniqKey="Paran D" first="D" last="Paran">D. Paran</name>
</author>
<author><name sortKey="Levartovsky, D" sort="Levartovsky, D" uniqKey="Levartovsky D" first="D" last="Levartovsky">D. Levartovsky</name>
</author>
<author><name sortKey="Litinsky, I" sort="Litinsky, I" uniqKey="Litinsky I" first="I" last="Litinsky">I. Litinsky</name>
</author>
<author><name sortKey="Kaufman, I" sort="Kaufman, I" uniqKey="Kaufman I" first="I" last="Kaufman">I. Kaufman</name>
</author>
<author><name sortKey="Wigler, I" sort="Wigler, I" uniqKey="Wigler I" first="I" last="Wigler">I. Wigler</name>
</author>
<author><name sortKey="Mendelson, E" sort="Mendelson, E" uniqKey="Mendelson E" first="E" last="Mendelson">E. Mendelson</name>
</author>
<author><name sortKey="Elkayam, O" sort="Elkayam, O" uniqKey="Elkayam O" first="O" last="Elkayam">O. Elkayam</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F1BEADA3E98709F72306672C235D47546767CB17</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1136/ard.2005.036434</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-CJWVBJG1-0/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002359</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002359</idno>
<idno type="wicri:Area/Istex/Curation">002359</idno>
<idno type="wicri:Area/Istex/Checkpoint">000B00</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000B00</idno>
<idno type="wicri:doubleKey">0003-4967:2006:Fomin I:vaccination:against:influenza</idno>
<idno type="wicri:Area/Main/Merge">001C44</idno>
<idno type="wicri:Area/Main/Curation">001C32</idno>
<idno type="wicri:Area/Main/Exploration">001C32</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers</title>
<author><name sortKey="Fomin, I" sort="Fomin, I" uniqKey="Fomin I" first="I" last="Fomin">I. Fomin</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Caspi, D" sort="Caspi, D" uniqKey="Caspi D" first="D" last="Caspi">D. Caspi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Levy, V" sort="Levy, V" uniqKey="Levy V" first="V" last="Levy">V. Levy</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Central Virology Laboratory, Public Health Services, Ministry of Health, Sheba Medical Centre, Tel-Hashomer</wicri:regionArea>
<wicri:noRegion>Tel-Hashomer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Varsano, N" sort="Varsano, N" uniqKey="Varsano N" first="N" last="Varsano">N. Varsano</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Central Virology Laboratory, Public Health Services, Ministry of Health, Sheba Medical Centre, Tel-Hashomer</wicri:regionArea>
<wicri:noRegion>Tel-Hashomer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shalev, Y" sort="Shalev, Y" uniqKey="Shalev Y" first="Y" last="Shalev">Y. Shalev</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Central Virology Laboratory, Public Health Services, Ministry of Health, Sheba Medical Centre, Tel-Hashomer</wicri:regionArea>
<wicri:noRegion>Tel-Hashomer</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Paran, D" sort="Paran, D" uniqKey="Paran D" first="D" last="Paran">D. Paran</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Levartovsky, D" sort="Levartovsky, D" uniqKey="Levartovsky D" first="D" last="Levartovsky">D. Levartovsky</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Litinsky, I" sort="Litinsky, I" uniqKey="Litinsky I" first="I" last="Litinsky">I. Litinsky</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kaufman, I" sort="Kaufman, I" uniqKey="Kaufman I" first="I" last="Kaufman">I. Kaufman</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wigler, I" sort="Wigler, I" uniqKey="Wigler I" first="I" last="Wigler">I. Wigler</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mendelson, E" sort="Mendelson, E" uniqKey="Mendelson E" first="E" last="Mendelson">E. Mendelson</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Faculty of Life Sciences, Bar-Ilan University, Ramat Gan</wicri:regionArea>
<wicri:noRegion>Ramat Gan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Elkayam, O" sort="Elkayam, O" uniqKey="Elkayam O" first="O" last="Elkayam">O. Elkayam</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Rheumatology, the Tel Aviv “Sourasky” Medical Centre and the “Sackler” Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2006-02">2006-02</date>
<biblScope unit="volume">65</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="191">191</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DMARD, disease modifying antirheumatic drug</term>
<term>GMT, geometric mean titre</term>
<term>HA, haemagglutinin</term>
<term>HAQ, Health Assessment Questionnaire</term>
<term>HIT, haemagglutination inhibition test</term>
<term>NA, neuraminidase</term>
<term>RF, rheumatoid factor</term>
<term>TNFα, tumour necrosis factor α</term>
<term>anti-TNFα</term>
<term>influenza</term>
<term>rheumatoid arthritis</term>
<term>vaccination</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Arthritis</term>
<term>Arthritis rheum</term>
<term>Blood cells</term>
<term>Disease activity</term>
<term>Dmards</term>
<term>Etanercept</term>
<term>Good humoral response</term>
<term>Haemagglutination</term>
<term>Health assessment questionnaire</term>
<term>Healthy controls</term>
<term>Humoral</term>
<term>Humoral response</term>
<term>Immune response</term>
<term>Immunogenicity</term>
<term>Infliximab</term>
<term>Influenza</term>
<term>Influenza vaccination</term>
<term>Influenza vaccine</term>
<term>Methotrexate</term>
<term>Morning stiffness</term>
<term>Pneumococcal vaccination</term>
<term>Reactive protein</term>
<term>Responder</term>
<term>Rheum</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatoid arthritis patients</term>
<term>Rheumatoid patients</term>
<term>Swollen joints</term>
<term>Systemic lupus erythematosus</term>
<term>Tnfa</term>
<term>Tnfa blockers</term>
<term>Tumour necrosis factor</term>
<term>Vaccination</term>
<term>Vaccine</term>
<term>Whole group</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: To assess the efficacy and safety of vaccination against influenza virus in patients with rheumatoid arthritis, with special emphasis on the effect of disease modifying antirheumatic drugs (DMARDs), including tumour necrosis factor α (TNFα) blockers. Methods: 82 rheumatoid patients and 30 healthy controls were vaccinated with a split-virion inactivated vaccine containing 15 μg haemagglutinin (HA) per dose of each of B/Hong Kong/330/2001 (HK), A/Panama/2007/99 (PAN), and A/New Caledonian/20/99 (NC). Disease activity was assessed by tender and swollen joint count, morning stiffness, evaluation of pain, Health Assessment Questionnaire, ESR, and C reactive protein on the day of vaccination and six weeks later. Haemagglutination inhibiting (HI) antibodies were tested by a standard WHO procedure. Response was defined as a fourfold or more rise in HI antibodies six weeks after vaccination, or seroconversion in patients with a non-protective baseline level of antibodies (<1/40). Geometric mean titres (GMT) were calculated to assess the immunity of the whole group. Results: Six weeks after vaccination, a significant increase in GMT for each antigen was observed in both groups, this being higher in the healthy group for HK (p = 0.004). The percentage of responders was lower in rheumatoid patients than healthy controls (significant for HK). The percentage of responders was not affected by prednisone or any DMARD, including methotrexate, infliximab, and etanercept. Indices of disease activity remained unchanged. Conclusions: Influenza virus vaccine generated a good humoral response in rheumatoid patients, although lower than in healthy controls. The response was not affected by the use of prednisone or DMARDs.</div>
</front>
</TEI>
<affiliations><list><country><li>Israël</li>
</country>
</list>
<tree><country name="Israël"><noRegion><name sortKey="Fomin, I" sort="Fomin, I" uniqKey="Fomin I" first="I" last="Fomin">I. Fomin</name>
</noRegion>
<name sortKey="Caspi, D" sort="Caspi, D" uniqKey="Caspi D" first="D" last="Caspi">D. Caspi</name>
<name sortKey="Elkayam, O" sort="Elkayam, O" uniqKey="Elkayam O" first="O" last="Elkayam">O. Elkayam</name>
<name sortKey="Kaufman, I" sort="Kaufman, I" uniqKey="Kaufman I" first="I" last="Kaufman">I. Kaufman</name>
<name sortKey="Levartovsky, D" sort="Levartovsky, D" uniqKey="Levartovsky D" first="D" last="Levartovsky">D. Levartovsky</name>
<name sortKey="Levy, V" sort="Levy, V" uniqKey="Levy V" first="V" last="Levy">V. Levy</name>
<name sortKey="Litinsky, I" sort="Litinsky, I" uniqKey="Litinsky I" first="I" last="Litinsky">I. Litinsky</name>
<name sortKey="Mendelson, E" sort="Mendelson, E" uniqKey="Mendelson E" first="E" last="Mendelson">E. Mendelson</name>
<name sortKey="Paran, D" sort="Paran, D" uniqKey="Paran D" first="D" last="Paran">D. Paran</name>
<name sortKey="Shalev, Y" sort="Shalev, Y" uniqKey="Shalev Y" first="Y" last="Shalev">Y. Shalev</name>
<name sortKey="Varsano, N" sort="Varsano, N" uniqKey="Varsano N" first="N" last="Varsano">N. Varsano</name>
<name sortKey="Wigler, I" sort="Wigler, I" uniqKey="Wigler I" first="I" last="Wigler">I. Wigler</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C32 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C32 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:F1BEADA3E98709F72306672C235D47546767CB17
   |texte=   Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers

Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri